https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:15298 Wed 11 Apr 2018 15:43:38 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34602 Tue 03 Sep 2019 18:30:54 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36190 measured during nighttime ambulatory BP monitoring (ABPM) and basal MAP estimated using a standardized protocol. Materials and methods: For a cohort of 137 consecutive patients, aged ≥40 years, who recently underwent ABPM, a blinded investigator estimated basal MAP from up to five most recent clinic BP measurements. Both basal MAP values, measured and estimated, were compared pairwise for each participant. Results: We traced a median of 4 [interquartile range 3-5] previous BP measurements per patient over a median period of 132 [interquartile range 55-277] days up until the ABPM test. The estimated basal MAP (mean 88 ± 8 mmHg) was linearly related (Pearson's r = 0.41, p = 0.0001) to the measured basal MAP (mean 88 ± 12 mmHg). Bland-Altman plot revealed a mean bias of 0.3 mmHg with agreement limits of ±22 mmHg. Conclusions: The mean bias between estimated and measured values for basal MAP was insignificant and modest. When a recent nighttime ABPM is unavailable, a protocol based on recent clinic BP readings can be used to estimate patient's basal MAP. Study registration: Australian New Zealand Clinical Trials Registry ACTRN12613001382763.]]> Thu 27 Feb 2020 09:35:33 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38730 Thu 20 Jan 2022 14:18:02 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:12231 Thu 11 Jul 2019 14:52:21 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7235 Sat 24 Mar 2018 08:33:45 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18542 Sat 24 Mar 2018 07:50:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28259 Sat 24 Mar 2018 07:28:34 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27060 Sat 24 Mar 2018 07:25:21 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47511 Mon 23 Jan 2023 12:08:26 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:723 Fri 23 Mar 2018 17:52:51 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44494 Fri 14 Oct 2022 09:04:40 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49423 100) was determined from simulations for four previously proposed treatment regimens: (i) 400 mg once daily, (ii) an 800 mg loading dose followed by 400 mg once daily, (iii) 400 mg twice daily, and (iv) a 12 mg/kg loading dose followed by 6 mg/kg once daily. The effect of body weight (40, 70, 120 kg) and renal function (continuous renal replacement therapy (CRRT); 20, 60, 120, 180 mL/min creatinine clearance) on PTA was assessed. Results: Early (0–48 h) fluconazole target attainment for infections with a minimum inhibitory concentration (MIC) of 2 mg/L was highly variable. PTA was highest with an 800 mg loading dose for underweight (40 kg) patients and with a 12 mg/kg loading dose for the remainder. End-of-treatment PTA was highest with the 400 mg twice daily maintenance dosing for patients who were under- or normal weight and 6 mg/kg maintenance dosing for overweight (120 kg) patients. None of the fluconazole regimens reliably attained early targets for MICs of ≥4 mg/L. Conclusion: Current fluconazole dosing regimens do not achieve adequate early target attainment in critically ill adults, particularly in those who are overweight, have higher creatinine clearance, or are undergoing CRRT. Current fluconazole dosing strategies are generally inadequate to treat organisms with an MIC of ≥4 mg/L.]]> Fri 12 May 2023 15:09:13 AEST ]]>